BRPI0414699A - formulações de acetato de anecortave e acetonida de triancinolona para injeção - Google Patents

formulações de acetato de anecortave e acetonida de triancinolona para injeção

Info

Publication number
BRPI0414699A
BRPI0414699A BRPI0414699-9A BRPI0414699A BRPI0414699A BR PI0414699 A BRPI0414699 A BR PI0414699A BR PI0414699 A BRPI0414699 A BR PI0414699A BR PI0414699 A BRPI0414699 A BR PI0414699A
Authority
BR
Brazil
Prior art keywords
injection
triamcinolone acetonide
anecortave acetate
formulations
acetonide formulations
Prior art date
Application number
BRPI0414699-9A
Other languages
English (en)
Inventor
Rajni Jani
Ernesto J Castillo
Wesley Wehsin Han
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0414699A publication Critical patent/BRPI0414699A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçõES DE ACETATO DE ANECORTAVE E ACETONIDA DE TRIANCINOLONA PARA INJEçãO". A presente invenção refere-se a composições injetáveis de acetonida de triancinolona ou acetato de anecortave. As composições são particularmente adequadas para injeção no segmento posterior do olho para tratar doenças oftálmicas.
BRPI0414699-9A 2003-09-23 2004-09-02 formulações de acetato de anecortave e acetonida de triancinolona para injeção BRPI0414699A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50538603P 2003-09-23 2003-09-23
PCT/US2004/028598 WO2005032510A1 (en) 2003-09-23 2004-09-02 Triamcinolone acetonide and anecortave acetate formulations for injection

Publications (1)

Publication Number Publication Date
BRPI0414699A true BRPI0414699A (pt) 2006-11-28

Family

ID=34421523

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414699-9A BRPI0414699A (pt) 2003-09-23 2004-09-02 formulações de acetato de anecortave e acetonida de triancinolona para injeção

Country Status (13)

Country Link
US (1) US20050065137A1 (pt)
EP (1) EP1663144A1 (pt)
JP (1) JP2007506678A (pt)
KR (1) KR20060095974A (pt)
CN (1) CN1852700A (pt)
AR (1) AR045943A1 (pt)
AU (1) AU2004277864A1 (pt)
BR (1) BRPI0414699A (pt)
CA (1) CA2539023A1 (pt)
MX (1) MXPA06003185A (pt)
RU (1) RU2006113593A (pt)
TW (1) TW200518760A (pt)
WO (1) WO2005032510A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
ITRM20050547A1 (it) * 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
SI2262506T1 (sl) * 2008-03-11 2014-07-31 Alcon Research, Ltd. Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo
TWI580441B (zh) * 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
CN101893619B (zh) * 2010-02-10 2013-11-13 上海蓝怡科技有限公司 改进乳胶悬浊液稳定性的方法
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
SG11201503637SA (en) * 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
KR102282973B1 (ko) 2013-05-03 2021-07-27 클리어사이드 바이오메디컬, 인코포레이드 안구용 주사를 위한 장치 및 방법
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
AU2019207515B2 (en) * 2018-01-10 2024-11-14 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
CA2289618A1 (en) * 1997-05-14 1998-11-19 Shin-Ichi Yasueda Aqueous suspension preparations with excellent redispersibility
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
AU2001278779A1 (en) * 2000-08-25 2002-03-04 Senju Pharmaceutical Co. Ltd. Aqueous suspension preparations
AU2002243760A1 (en) * 2001-01-30 2002-08-12 Board Of Regents University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
EP1539182A4 (en) * 2002-08-05 2010-01-20 Alcon Inc USE OF ANECORTAVEACETATE FOR THE PROTECTION OF THE SEVERING POWER OF PATIENTS WITH AGE-RELATED MACULAR AGENCY
US20060154910A1 (en) * 2003-02-20 2006-07-13 Bingaman David P Use of steroids to treat ocular disorders
AU2004212900A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
US20040186084A1 (en) * 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use

Also Published As

Publication number Publication date
WO2005032510A1 (en) 2005-04-14
CA2539023A1 (en) 2005-04-14
CN1852700A (zh) 2006-10-25
MXPA06003185A (es) 2006-06-23
EP1663144A1 (en) 2006-06-07
AR045943A1 (es) 2005-11-16
TW200518760A (en) 2005-06-16
US20050065137A1 (en) 2005-03-24
KR20060095974A (ko) 2006-09-05
RU2006113593A (ru) 2006-08-27
AU2004277864A1 (en) 2005-04-14
JP2007506678A (ja) 2007-03-22

Similar Documents

Publication Publication Date Title
BRPI0414699A (pt) formulações de acetato de anecortave e acetonida de triancinolona para injeção
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
ATE418325T1 (de) Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon- acetonid und hyaluronsäure
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
MX2010003774A (es) Formulaciones oftalmicas acuosas.
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
HRP20050781B1 (hr) Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu
BR0312232A (pt) Inibidores de caspases e seus usos
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
BR0211604A (pt) Inibidores de integrina para o tratamento de doenças do olho
BRPI0413742A (pt) derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
BR0313546A (pt) Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
EA200600998A1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
WO2005041870A3 (en) Composition and method for the treatment of eye disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A, 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.